Drug intelligence / Profile preview

AGX-149

Development stage: Preclinical
Lead developer: AgonOx
Administration: Parenteral

Overview

AGX-149 is a novel biological drug candidate developed by AgonOx for the treatment of cancer. It acts as a T-cell costimulatory target, functioning as a T lymphocyte stimulant to enhance immune responses against tumors. The drug is classified as an antineoplastic agent and represents a new molecular entity in this therapeutic area. As of the latest updates, AGX-149 remains in preclinical development with no clinical trials or regulatory approvals reported[1][2].

Other names: AGX 149AGX149AGX-149

Beyond the preview

Go deeper on AGX-149.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGX-149.

Explore the full profile